MX374759B - Inhibidores de tirosina cinasa de bruton. - Google Patents

Inhibidores de tirosina cinasa de bruton.

Info

Publication number
MX374759B
MX374759B MX2016006351A MX2016006351A MX374759B MX 374759 B MX374759 B MX 374759B MX 2016006351 A MX2016006351 A MX 2016006351A MX 2016006351 A MX2016006351 A MX 2016006351A MX 374759 B MX374759 B MX 374759B
Authority
MX
Mexico
Prior art keywords
compounds
btk
bruton
tyrosine kinase
kinase inhibitors
Prior art date
Application number
MX2016006351A
Other languages
English (en)
Other versions
MX2016006351A (es
Inventor
Francisco Javier Lopez-Tapia
Norman Kong
Romyr Dominique
Sung-Sau So
Yan Lou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016006351A publication Critical patent/MX2016006351A/es
Publication of MX374759B publication Critical patent/MX374759B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta solicitud describe compuestos de acuerdo con la fórmula genérica (I): en donde todas las variables se definen como se describe en el presente documento, que inhiben Btk. Los compuestos descritos en el presente documento son útiles para modular la actividad de Btk y tratar enfermedades asociadas con exceso de actividad Btk. Los compuestos son útiles para el tratamiento de enfermedades oncológicas, autoinmunes, e inflamatorias causadas por la activación de células B aberrante. También se describen composiciones que contienen compuestos de Fórmula I y por lo menos un portador, diluyente o excipiente.
MX2016006351A 2013-12-13 2014-12-10 Inhibidores de tirosina cinasa de bruton. MX374759B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361915588P 2013-12-13 2013-12-13
PCT/EP2014/077116 WO2015086636A1 (en) 2013-12-13 2014-12-10 Inhibitors of bruton's tyrosine kinase

Publications (2)

Publication Number Publication Date
MX2016006351A MX2016006351A (es) 2016-08-01
MX374759B true MX374759B (es) 2025-03-06

Family

ID=52016583

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006351A MX374759B (es) 2013-12-13 2014-12-10 Inhibidores de tirosina cinasa de bruton.

Country Status (12)

Country Link
US (1) US9802920B2 (es)
EP (1) EP3080098B1 (es)
JP (1) JP6294490B2 (es)
KR (1) KR101822767B1 (es)
CN (1) CN105722834B (es)
BR (1) BR112016013541B1 (es)
CA (1) CA2929785C (es)
HK (1) HK1226070B (es)
MX (1) MX374759B (es)
RU (1) RU2653500C2 (es)
TW (1) TWI540130B (es)
WO (1) WO2015086636A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2653504C2 (ru) * 2013-12-13 2018-05-10 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
WO2015099127A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬
WO2016204261A1 (ja) * 2015-06-17 2016-12-22 中外製薬株式会社 アミノピラゾール誘導体
EA202192738A1 (ru) 2019-04-12 2022-03-17 С4 Терапьютикс, Инк. Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316466B1 (en) 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
US20030236288A1 (en) 2002-02-28 2003-12-25 Karl Schoenafinger Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
UA79804C2 (en) 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
AU2004256029A1 (en) 2003-06-24 2005-01-20 Co/Cie Crompton Fungicidal phenoxyphenylhydrazine derivatives
BRPI0411825B8 (pt) 2003-06-26 2021-05-25 Novartis Ag inibidores de p38 quinase a base de heterociclo de 5 elementos, seus processos de preparação e seus usos, bem como composição farmacêutica
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique
US20080269291A1 (en) 2005-11-18 2008-10-30 Kerns Jeffrey K Chemical Compounds
US8026257B2 (en) 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
AR084370A1 (es) 2009-08-07 2013-05-15 Chugai Pharmaceutical Co Ltd Derivados de aminopirazol
CA2771026A1 (en) 2009-09-24 2011-03-31 F. Hoffmann-La Roche Ag Indole derivatives as crac modulators
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
US9840515B2 (en) 2010-12-09 2017-12-12 University of Pittsburgh—of the Commonwealth System of Higher Education Protein kinase D inhibitors
JP5620417B2 (ja) * 2011-02-07 2014-11-05 中外製薬株式会社 アミノピラゾール誘導体を含む医薬
JP5808869B2 (ja) * 2011-11-03 2015-11-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二環式ピペラジン化合物

Also Published As

Publication number Publication date
TWI540130B (zh) 2016-07-01
KR101822767B1 (ko) 2018-01-26
MX2016006351A (es) 2016-08-01
JP6294490B2 (ja) 2018-03-14
BR112016013541B1 (pt) 2021-03-02
HK1226070B (zh) 2017-09-22
EP3080098A1 (en) 2016-10-19
US9802920B2 (en) 2017-10-31
CN105722834A (zh) 2016-06-29
TW201536773A (zh) 2015-10-01
RU2653500C2 (ru) 2018-05-10
US20160304497A1 (en) 2016-10-20
JP2016540023A (ja) 2016-12-22
CA2929785A1 (en) 2015-06-18
WO2015086636A1 (en) 2015-06-18
KR20160081982A (ko) 2016-07-08
CA2929785C (en) 2018-02-13
CN105722834B (zh) 2017-12-22
EP3080098B1 (en) 2017-12-06

Similar Documents

Publication Publication Date Title
CO2019006622A2 (es) Derivados de pirazol como inhibidores de malt1
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
MX380907B (es) Compuestos útiles como inhibidores de cinasa.
SG194728A1 (en) Inhibitors of bruton's tyrosine kinase
PH12014500128A1 (en) Inhibitors of bruton's tyrosine kinase
MX374758B (es) Inhibidores de tirosina cinasa de bruton.
BR112015032595A8 (pt) inibidores de ido
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201691514A1 (ru) Соединения
GEP20166474B (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
MX2015005015A (es) Inhibidores heteroarilo de pde4.
GEP20166554B (en) Nitrogenated heterocyclic compound
PH12015502737A1 (en) Novel fused pyrimidine compound or salt thereof
WO2014064131A3 (en) Inhibitors of bruton's tyrosine kinase
MX2018007075A (es) Compuestos policiclicos como inhibidores de tirosina quinasa de bruton.
MX2015010466A (es) Inhibidores de tirosina cinasa de bruton.
MX2016006763A (es) Inhibidores de tirosina cinasa de bruton.
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
EA201790207A1 (ru) Новые замещенные пиримидиновые соединения
MX349548B (es) Compuestos de tienopirimidina.
MX2015010983A (es) Inhibidores de tirosina-cinasa de bruton.
EA201590379A1 (ru) Пирролопиразолы, используемые в качестве блокаторов кальциевых каналов n-типа
MX374759B (es) Inhibidores de tirosina cinasa de bruton.
MX2015013936A (es) Compuestos de pirimidina condensada sustituida.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: F. HOFFMANN-LA ROCHE AG

FG Grant or registration